All In MedTech

FDA Clearance Tracker · P020027

DIMENSION FPSA FLEX REAGENT CARTRIDGE AND DIMENSION T/F PSA CALIBRATOR FOR DIMENSION RXL AND XPAND SYSTEMS

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jan 24, 2003 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jan 24, 2003

Approved

Time to decision

203 days

Received Jul 5, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P020027
Device name
DIMENSION FPSA FLEX REAGENT CARTRIDGE AND DIMENSION T/F PSA CALIBRATOR FOR DIMENSION RXL AND XPAND SYSTEMS
Applicant location
Newark, DE
Received
Jul 5, 2002
Decided
Jan 24, 2003
Decision
Approved
Supplements
41 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MTG

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE DIMENSION FPSA FLEX REAGENT CARTRIDGE AND DIMENSION T/F PSA CALIBRATOR FOR DIMENSION RXL AND XPAND SYSTEMS. THE DIMENSION FPSA FLEX REAGENT CARTRIDGE IS INDICATED FOR: THE FPSA METHOD FOR THE DIMENSION CLINICAL CHEMISTRY SYSTEM WITH THE HETEROGENOUS IMMUNOASSAY MODULE IS AN IN VITRO DIAGNOSTIC TEST INTENDED TO QUANTITATIVELY MEASURE FREE PROSTATE SPECIFIC ANTIGEN (FPSA) IN HUMAN SERUM. MEASUREMENT OF FPSA ARE USED IN CONJUNCTION WITH TOTAL PSA (TPSA) METHOD ON DIMENSION SYSTEM TO CALCULATE FPSA TO TPSA RATIO EXPRESSED AS A PERCENT FPSA. THE PERCENT FPSA IS USED AS AN AID IN DISTINGUISHING PROSTATE CANCER FROM BENIGN PROSTATE CONDITIONS IN MEN 50 YEARS OR OLDER WITH TPSA OF 4.0 TO 10.0 NG/ML [UG/L] AND DIGITAL RECTAL EXAMINATION (DRE) FINDINGS NOT SUSPICIOUS FOR CANCER. PROSTATE BIOPSY IS REQUIRED FOR DIAGNOSIS OF CANCER. THE DIMENSION T/F PSA CALIBRATOR IS INDICATED FOR: THE T/F PSA CALIBRATOR IS AN IN VITRO DIAGNOSTIC PRODUCT INTENDED TO BE USED TO CALIBRATE THE TOTAL (TPSA) AND FREE (FPSA) PROSTATE SPECIFIC ANTIGEN METHODS FOR THE DIMENSION CLINICAL CHEMISTRY SYSTEM WITH THE HETEROGENEOUS IMMUNOASSAY MODULE. THIS PRODUCT WAS DESIGNED TO MEET THE NEEDS OF USERS TO ASSURE ACCURATE RESULTS OVER THE ASSAY RANGE OF THESE METHODS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MTG. The earliest in FDA's data is P950021, decided Dec 22, 1995.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Siemens Healthcare Diagnostics

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.